Biovest Names Lymphoma Key Opinion Leader from MD Anderson Cancer Center to Scientific Advisory Board
September 11 2012 - 07:45AM
Business Wire
Biovest International, Inc. (OTCQB: BVTI), a majority-owned
subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI),
today announced that it appointed Sattva S. Neelapu, M.D.,
Associate Professor, Department of Lymphoma/Myeloma, Division of
Cancer Medicine at The University of Texas MD Anderson Cancer
Center to Biovest’s Scientific Advisory Board.
Earlier this year, Dr. Neelapu presented on BiovaxID™, Biovest’s
personalized cancer vaccine for the treatment of non-Hodgkin’s
lymphoma, at a number of meetings with European national medicine
agencies that led to Biovest’s decision to seek marketing approval
in Europe. Supported via a grant awarded by the National Institutes
of Health (NIH), Dr. Neelapu is also conducting additional analysis
from the BiovaxID Phase III clinical trial. With a specialized
focus on tumor immunology and cancer vaccines, Dr. Neelapu is the
recipient of numerous awards from the American Society of Clinical
Oncology (ASCO), American Association for Cancer Research (AACR)
and U.S. National Cancer Institute (NCI).
In other news, Biovest announced that it will recognize the
importance of World Lymphoma Awareness Day on September 15th by
presenting and exhibiting at a patient/caregiver educational
symposium in Chicago titled, “Follicular Lymphoma: On the Road to a
Cure”. On the agenda, Stephen J. Schuster, M.D. is scheduled to
discuss the emerging role of cancer vaccines to improve outcomes in
the treatment of lymphoma. Dr. Schuster serves as the Robert and
Margarita Louis-Dreyfus Associate Professor in Chronic Lymphocytic
Leukemia and Lymphoma Clinical Care and Research and Director of
the Lymphoma Program at the Abramson Cancer Center of the
University of Pennsylvania. He also serves on Biovest’s Scientific
Advisory Board and has been instrumental in the clinical
development of BiovaxID, presenting vaccine trial results at major
peer-review cancer meetings including at the American Society of
Clinical Oncology (ASCO) and at the American Society of Hematology
(ASH).
For more information on the “Road to a Cure” lymphoma event,
please visit: http://www.road2cure.com/
Biovest’s President & CEO, Samuel S. Duffey, stated, “With
the addition of Dr. Neelapu, we continue to assemble a world-class
Scientific Advisory Board. To have such an accomplished group of
key opinion leaders contributing to the advancement of BiovaxID is
a testament to the science and potential of our personalized cancer
vaccine technology and reflects a commitment to improve treatment
outcomes for lymphoma patients.”
Biovest also reported that a multi-part series of articles are
being published on the website, www.LymphomaInfo.net, highlighting
the promise of BiovaxID as a personalized cancer vaccine for the
treatment of non-Hodgkin’s lymphoma. The articles can be accessed
in the Media Center at Biovest’s corporate website at:
http://www.biovest.com/investor-relations/media-center
About Biovest International,
Inc.
Biovest International, Inc. develops active immunotherapies
(cancer vaccines) which treat and diminish the aggressiveness of
B-cell non-Hodgkin’s lymphoma, a cancer of the immune system. The
Company’s lead personalized cancer vaccine product candidate,
BiovaxID™, has been evaluated in three clinical trials conducted in
collaboration with the U.S. National Cancer Institute (NCI)
demonstrating that BiovaxID increases the duration of cancer
remission following chemotherapy and induces immune responses which
correlate highly with long-term survival. Biovest is currently in
the process of pursuing European and Canadian marketing approvals
for BiovaxID.
Headquartered in Tampa, Florida with its bio-manufacturing
facility based in Minneapolis, Minnesota, Biovest is
publicly-traded on the OTCQB™ Market with the stock-ticker symbol
“BVTI”, and is a majority-owned subsidiary of Accentia
Biopharmaceuticals, Inc. (OTCQB: ABPI).
For further information, please visit:
http://www.biovest.com
Forward-Looking
Statements:
Statements in this press release that are not strictly
historical in nature constitute "forward-looking statements."
Such statements include, but are not limited to, statements
about Biovest and its product candidate, BiovaxID™ and any other
statements relating to products, product candidates, product
development programs, the FDA, the EMA, Health Canada or clinical
study process including the commencement, process, or completion of
clinical trials or the regulatory process. Such statements
may include, without limitation, statements with respect to the
Company's plans, objectives, expectations and intentions, and other
statements identified by words such as "may," "could," "would,"
"should," "believes," "expects," "anticipates," "estimates,"
"intends," "plans," or similar expressions. In particular (and
without limitation), statements regarding the timing of anticipated
filing of a Marketing Authorization Application for BiovaxID with
the EMA or a New Drug Submission for BiovaxID with Health Canada,
pre-filing meetings with the FDA or other jurisdictions and/or
commercial plans reflect current expectations but are subject to
inherent risks of delay in compilation and finalization of all
components of the licensing application. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other factors that may cause the actual results of Biovest to be
materially different from historical results or from any results
expressed or implied by such forward-looking statements.
These factors include, but are not limited to, risks and
uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or
delays in obtaining regulatory approval for product candidates;
competition from other pharmaceutical or biotechnology companies;
and the additional risks discussed in filings with the Securities
and Exchange Commission. All forward-looking statements are
qualified in their entirety by this cautionary statement, and
Biovest undertakes no obligation to revise or update this news
release to reflect events or circumstances after the date
hereof. The product names used in this statement are for
identification purposes only. All trademarks and registered
trademarks are the property of their respective owners.